Publicacións en colaboración con investigadores/as de Hospital Universitari de Bellvitge (9)

2024

  1. PCSK9 inhibitors on the management of primary and secondary cardiovascular prevention

    Lipids in Health and Disease , Vol. 23, Núm. 1

2022

  1. Differences in the diabetogenic effect of statins in patients with prediabetes. The PRELIPID study

    Medicina Clinica, Vol. 158, Núm. 11, pp. 531-539

  2. SEA 2022 Standards for Global Control of Cardiovascular Risk

    Clinica e Investigacion en Arteriosclerosis, Vol. 34, Núm. 3, pp. 130-179

2020

  1. Incidence of cardiovascular events and changes in the estimated risk and treatment of familial hypercholesterolemia: the SAFEHEART registry

    Revista Espanola de Cardiologia, Vol. 73, Núm. 10, pp. 828-834

2017

  1. Consecución de objetivos terapéuticos de colesterol LDL en niños y adolescentes con hipercolesterolemia familiar. Registro longitudinal SAFEHEART

    Revista Espanola de Cardiologia, Vol. 70, Núm. 6, pp. 444-450

2016

  1. Clinical and molecular characteristics of homozygous familial hypercholesterolemia patients: Insights from SAFEHEART registry

    Journal of Clinical Lipidology, Vol. 10, Núm. 4, pp. 953-961

2015

  1. Statins do not increase the risk of developing type 2 diabetes in familial hypercholesterolemia: The SAFEHEART study

    International Journal of Cardiology, Vol. 201, pp. 79-84

2008

  1. Cardiovascular disease in familial hypercholesterolaemia: Influence of low-density lipoprotein receptor mutation type and classic risk factors

    Atherosclerosis, Vol. 200, Núm. 2, pp. 315-321

2002

  1. Heterozygous familial hypercholesterolemia in Spain. Description of 819 non related cases

    Medicina Clinica, Vol. 118, Núm. 13, pp. 487-492